National Bank of Canada
EWTX icon

National Bank of Canada’s Edgewise Therapeutics EWTX Stock Holding History

National Bank of Canada’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40
Closed -$649 – 2955
2025
Q3 		$649 Hold
40
– – ﹤0.01% 2675
2025
Q2 		$524 Buy
+40
New +$577 ﹤0.01% 2762
2025
Q1 		– Sell
-3
Closed -$80 – 2938
2024
Q4 		$80 Buy
3
+2
+200% +$64 ﹤0.01% 2810
2024
Q3 		$27 Buy
+1
New +$20 ﹤0.01% 2627

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

National Bank of Canada's EWTX Position: Q4 2025 in Review

National Bank of Canada sold out of Edgewise Therapeutics (EWTX) in Q4 2025, closing a stake of 40 shares — an estimated $649 sold.

National Bank of Canada first reported a position in EWTX in Q3 2024 and held it in 4 quarters. The position peaked at $649 in Q3 2025. 199 funds tracked by Wall St. Rank hold EWTX as of Q4 2025.

  • National Bank of Canada reported no remaining Edgewise Therapeutics position as of Q4 2025 after selling out during the quarter.
  • National Bank of Canada sold 40 Edgewise Therapeutics shares in Q4 2025, an estimated $649.
  • National Bank of Canada first reported a position in Edgewise Therapeutics in Q3 2024 and held it in 4 quarters.
  • National Bank of Canada's Edgewise Therapeutics position peaked at $649 in Q3 2025.
  • 199 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2025.

Based on National Bank of Canada's 13F filing for Q4 2025, filed 17 Feb 2026.